Haisco Pharmaceutical (SHE:002653) received approval from China's National Medical Products Administration for the marketing of the iptacopan succinate tablets, according to a Thursday disclosure on the Shenzhen bourse.
The drug will be used for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria.
The pharmaceutical company's shares jumped 4% during the afternoon trade.